TrialCancer science2020

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.

Kazutaka Sunami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.